Gilead Sciences (GILD) Downgraded by BidaskClub to Sell

Gilead Sciences (NASDAQ:GILD) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a report released on Tuesday.

Several other equities analysts also recently weighed in on GILD. Zacks Investment Research downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, September 11th. ValuEngine cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 13th. Royal Bank of Canada started coverage on Gilead Sciences in a report on Thursday, September 14th. They issued an “outperform” rating and a $94.00 target price on the stock. Leerink Swann reissued a “market perform” rating and issued a $87.00 price objective (up from $82.00) on shares of Gilead Sciences in a research report on Wednesday, September 20th. Finally, Mizuho reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $85.03.

Gilead Sciences (NASDAQ:GILD) opened at $74.40 on Tuesday. The stock has a market capitalization of $97,160.00, a P/E ratio of 8.46, a PEG ratio of -1.58 and a beta of 1.13. Gilead Sciences has a one year low of $63.76 and a one year high of $86.27. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. The business had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.75 EPS. research analysts anticipate that Gilead Sciences will post 8.53 earnings per share for the current year.

In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the completion of the transaction, the insider now directly owns 3,070,099 shares in the company, valued at $230,656,537.87. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 461,666 shares of company stock valued at $34,072,567. 1.30% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of GILD. BlackRock Inc. lifted its position in Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. Vanguard Group Inc. lifted its position in Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Bank of New York Mellon Corp lifted its position in Gilead Sciences by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares during the period. FMR LLC lifted its position in Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the period. Finally, Northern Trust Corp lifted its position in Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares during the period. Institutional investors and hedge funds own 75.94% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Gilead Sciences (GILD) Downgraded by BidaskClub to Sell” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/09/gilead-sciences-gild-downgraded-by-bidaskclub-to-sell.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit